Asthma Drugs Get New Rules After FDA Finds Death Link

Law360, New York (February 18, 2010, 6:35 PM EST) -- The U.S. Food and Drug Administration has moved to restrict the use of long-acting beta agonists, asthma drugs marketed by AstraZeneca PLC, Novartis AG and GlaxoSmithKline PLC that FDA analyses have linked with worsening asthma symptoms and death in some patients.

LABAs should never be used alone in the treatment of asthma in children and adults, the FDA said in a statement Thursday.

Manufacturers will be required to include that warning on the drug labels and take steps to reduce the overall use of the medications...
To view the full article, register now.